laitimes

Yahong Pharma released its 2023 annual report: the global phase III clinical trial of its core product APL-1702 was successfully accepted by the domestic NDA of APL-1706 The "hematopoiesis" of the specialist commercialization team has begun to bear fruit

author:Bitsusha

Read on